An Act To Enact the Maine Psilocybin Services Act
Maine Legislature, Session 130, LD 1582
Committee Amendment CA_A_S464 (Senate)
Amends: 5 MRSA §12004

COMMITTEE AMENDMENT" A "to S.P. 496, L.D. 1582, "An Act To Enact the 
Maine Psilocybin Services Act" 
Amend the bill by striking out the title and substituting the following: 
'An Act To Establish the Maine Psychedelic Advisory Board' 
Amend the bill by striking out everything after the enacting clause and inserting the 
following: 
'Sec. 1. 5 MRSA §12004-1, sub-§47-J is enacted to read: 
47-J. 
Human 
Services 
Maine Psychedelic Advisory Board 
Expenses Plus 
$50/Day 
Sec. 2. 22 MRSA c. 556-B is enacted to read: 
CHAPTER 556-B 
MAINE PSYCHEDELIC ADVISORY BOARD 
§2357. Maine Psychedelic Advisory Board 
22MRSA 
§2357 
1. Establishment. The Maine Psychedelic Advisory Board, established in Title 5, 
section 12004-I, subsection 47-J and referred to in this chapter as "the board," is created 
within the department for the pm::poses of advising and making recommendations to the 
Legislature regarding the therapeutic uses of psychedelic drugs. 
2. Membership. The board consists of 19 members as follows: 
A. Three ex officio, nonvoting members: 
COMMITTEE AMENDMENT 
ROS 
COMMITTEE AMENDMENT" A" to S.P. 496, L.D. 1582 l S- <.-(lo.cf) 
(1) The Director of the Maine Center for Disease Control and Prevention within 
the department or the director's designee: 
(2) The State Health Officer or the officer's designee, unless the officer is also the 
Director of the Maine Center for Disease Control and Prevention, in which case, a 
designee of the director. The member of the board under this subparagraph must 
be a physician licensed under Title 32, chapter 36 or 48: and 
(3) The chair of the Statewide Coordinating Council for Public Health, established 
in Title 5, section 12004-G, subsection 14-G: 
B. The Attorney General or the Attorney General's designee, who serves as an ex 
officio, voting member; and 
C. Fifteen voting members appointed by the Governor as follows: 
(1) Four members who meet any of the requirements of this subparagraph: 
(a) A state employee who has technical expertise in the field of public health; 
(b) A representative from a district coordinating council for public health, 
established pursuant to section 412, subsection 4; 
(c) A representative of a federally recognized Indian tribe in the State; 
(d) 
A member of the Substance Use Disorder Services Commission, 
established in Title 5, section 12004-G, subsection 13-C; 
(e) 
A member of the Permanent Commission on the Status of Racial, 
Indigenous and Tribal Populations, established in Title 5, section 12004-J, 
subsection 19; 
(f) A member of the Palliative Care and Quality of Life Interdisciplinary 
Advisory Council, established in Title 5, section 12004-1, subsection 47-1; or 
(g) An individual who represents individuals who provide public health 
services directly to the public; 
(2) A psychologist licensed under Title 32, chapter 56 who has professional 
experience providing behavioral health services: 
(3) A physician licensed under Title 32, chapter 48; 
(4) A naturopathic doctor licensed under Title 32, chapter 113-B: 
(5) A member with expertise in the field of public health who has a background 
in academia; 
(6) Three members who meet any of the requirements of this subparagraph: 
(a) 
A person with professional expertise conducting scientific research 
regarding the use of psychedelic compounds in clinical therapy: 
(b) A person who has experience in the field of mycology: 
(c) A person who has experience in the field of ethnobotany; 
(d) A person who has experience in the field of psychopharmacology; or 
(e) A person who has experience in the field of psilocybin harm reduction: 
COMMITTEE AMENDMENT 
ROS 
COMMITTEE AMENDMENT" f+ "to S.P. 496, L.D. 1582 L 5- L{ (i--lJ 
(7) A member representing the Department of Administrative and Financial 
Services who has expertise working with the system developed and maintained by 
that department for tracking marijuana in accordance with section 2430-G, 
subsection 1, paragraph B or Title 28-B, section 105; and 
(8) Three at-large members. 
3. Terms; vacancies. Except for ex officio members, members of the board serve 
4-year terms and may be reappointed. Before the expiration of the term of a member, the 
Governor shall appoint a successor for a term beginning on January 1st of the next calendar 
year. Board members are not subject to legislative confirmation. If there is a vacancy under 
subsection 2, paragraph C, the Governor shall immediately appoint a successor to serve for 
the remainder of the unexpired term. 
4. Chair. The board shall annually elect one of its voting members to serve as chair. 
5. Meeting frequency. The board shall meet at least 4 times each year at regular 
intervals at a time and place determined by the chair or at least 8 voting members of the 
board. The board may meet at other times and places by the call of the chair or 8 voting 
members of the board. 
6. Quorum. At least 8 of the board's voting members constitutes a quorum. 
7. 
Establishment of subcommittees. The board may establish subcommittees 
necessary for the operation of the board. 
8. Expenses; reimbursement. Board members are entitled to compensation for 
service on the board and reimbursement for travel and board-related expenses in 
accordance with Title 5, section 12004-I, subsection 47-J. 
9. Duties. The board shall: 
A. Develop and maintain a long-term strategic plan for ensuring that psychedelic 
drugs, 
including 
but 
not 
limited 
to 
psilocybin 
and 
3,4-methylenedioxymethamphetamine, MDMA, become and remain a safe, accessible 
and affordable therapeutic option for persons who are 21 years of age or older and for 
whom psychedelic drugs may be appropriate; 
B. Review the scientific literature regarding the therapeutic use of psychedelic drugs, 
including but not limited to psilocybin and 3,4-methylenedioxymethamphetamine, 
MDMA; 
C. Study efforts by other states to adopt a legal framework for the therapeutic use of 
psychedelic 
drugs, 
including 
but 
not 
limited 
to 
psilocybin 
and 
3,4-methylenedioxymethamphetamine, MDMA; 
D. Monitor and study federal laws, regulations and policies regarding psychedelic 
drugs, 
including 
but 
not 
limited 
to 
psilocybin 
and 
3,4-methylenedioxymethamphetamine, MDMA; 
E. Determine the steps the State would need to take in order to establish and maintain 
a legal framework for the therapeutic use of psychedelic drugs, including but not 
limited to psilocybin and 3,4-methylenedioxymethamphetamine, MDMA, in the State; 
and 
COMMITTEE AMENDMENT 
COMMITTEE AMENDMENT" P., "to S.P. 496, L.D. 1582 (S-Y ~Yj 
F. Advise and make recommendations to the Legislature regarding a legal framework 
for the therapeutic use of psychedelic drugs, including but not limited to psilocybin and 
3,4-methylenedioxymethamphetamine, MDMA. Any recommendations by the board 
require the approval of 8 of the board's voting members. 
10. Report. By February 1st of each year, the board shall submit a report to the joint 
standing committee of the Legislature having jurisdiction over health and human services 
matters that includes information related to its strategic plan pursuant to subsection 9, 
paragraph A. 
Sec. 3. Initial terms. Notwithstanding the Maine Revised Statutes, Title 22, section 
2357, subsection 3, for the original appointments of 15 members by the Governor to the 
Maine Psychedelic Advisory Board, 7 members serve initial terms of 2 years and 8 
members serve initial terms of 4 years. 
Sec. 4. Initial report. By February 1, 2023, the Maine Psychedelic Advisory Board 
shall submit a report pursuant to the Maine Revised Statutes, Title 22, section 2357, 
subsection 10 to the joint standing committee of the Legislature having jurisdiction over 
health and human services matters that includes an update on its progress and any 
recommendations for legislation. The committee may report out legislation related to the 
report to the 131 st Legislature in 2023. 
Sec. 5. Appropriations and allocations. The following appropriations and 
allocations are made. 
HEALTH AND HUMAN SERVICES, DEPARTMENT OF 
Department of Health and Human Services Central Operations 0142 
Initiative: Provides funding for the per diem and other expenses of members of the Maine 
Psychedelic Advisory Board. 
GENERAL FUND 
All Other 
GENERAL FUND TOTAL 
2021-22 
$0 
$0 
2022-23 
$4,000 
$4,000 
Amend the bill by relettering or renumbering any nonconsecutive Part letter or section 
number to read consecutively. 
SUMMARY 
This amendment replaces the bill and changes the title. It establishes the Maine 
Psychedelic Advisory Board within the Department of Health and Human Services, and 
the board is composed of 19 members. It tasks the board with developing and maintaining 
a long-term strategic plan for ensuring that psychedelic drugs, including but not limited to 
psilocybin and 3,4-methylenedioxymethamphetamine, MDMA, become and remain a safe, 
8 
accessible and affordable therapeutic option for persons who are 21 years of age or older 
and for whom psychedelic drugs may be appropriate; reviewing scientific literature; 
studying similar efforts in other states; determining steps necessary to establish and 
maintain a legal framework for the therapeutic use of psychedelic drugs; advising and 
making recommendations to the Legislature; and monitoring federal laws and policies. It 
COMMITTEE AMENDMENT 
ROS 
COMMITTEE AMENDMENT" f'.J "to S.P. 496, L.D. 1582 (,S-L\Ln,~ 
requires the board to submit a report on its strategic plan to the joint standing committee of 
the Legislature having jurisdiction over health and human services matters by February 1, 
2023, and annually thereafter, and allows the committee to report out legislation. 
The amendment also adds an appropriations and allocations section. 
FISCAL NOTE REQUIRED 
(See attached) 
COMMITTEE AMENDMENT 
Approved: 03/17 /22 feae 
LD 1582 
LR211(02) 
An Act To Enact the Maine Psilocybin Services Act 
Fiscal Note for Bill as Amended by Committee Amendment '}}' ( S-y (QY) 
Committee: Health and Human Services 
Net Cost (Savings) 
General Fund 
Appropriations/ Allocations 
General Fund 
Fiscal Detail and Notes 
Fiscal Note Required: Yes 
Fiscal Note 
FY 2021-22 
FY 2022-23 
$0 
$4,000 
$0 
$4,000 
Projections 
FY2023-24 
$4,000 
$4,000 
Projections 
FY 2024-25 
$4,000 
$4,000 
This bill includes General Fund appropriations to the Department of Health and Human Services of $4,000 beginning 
in fiscal year 2022-23 for the per diem and other expenses of members of the Maine Psychedelic Advisory Board. 
Additional costs for the Office of the Attorney General to participate in the work of the board are assumed to be minor 
and can be absorbed within existing budgeted resources. 
LR0211(02) - Fiscal Note - Page 1 of 1